| 1.02 0.03 (3.03%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.85 | 1-year : | 3.93 |
| Resists | First : | 2.44 | Second : | 3.36 |
| Pivot price | 1.49  |
|||
| Supports | First : | 0.94 | Second : | 0.78 |
| MAs | MA(5) : | 1.19 |
MA(20) : | 1.55 |
| MA(100) : | 1.92 |
MA(250) : | 3.26 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 2.9 |
D(3) : | 8 |
| RSI | RSI(14): 33.9  |
|||
| 52-week | High : | 9.37 | Low : | 0.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SXTC ] has closed above bottom band by 5.2%. Bollinger Bands are 24.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.09 | 1.09 - 1.09 |
| Low: | 0.93 - 0.94 | 0.94 - 0.94 |
| Close: | 1.01 - 1.02 | 1.02 - 1.03 |
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
Wed, 17 Apr 2024
Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket - Markets Insider
Fri, 05 Apr 2024
China SXT Pharmaceuticals: Operational Risks and Profit Repatriation Challenges - TipRanks.com - TipRanks
Thu, 25 Jan 2024
SXTC, CORZ and ARDX are among pre market gainers - Seeking Alpha
Fri, 29 Dec 2023
Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Markets Insider
Thu, 05 Oct 2023
China SXT Pharma (NASDAQ: SXTC) to jump 2,500% - a purely technical move - Dhaka Tribune
Wed, 04 Oct 2023
China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 22 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 26 (K) |
| Shares Short P.Month | 83 (K) |
| EPS | -22.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.96 |
| Profit Margin | 0 % |
| Operating Margin | -995.1 % |
| Return on Assets (ttm) | -45.8 % |
| Return on Equity (ttm) | -141.7 % |
| Qtrly Rev. Growth | -22.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3 |
| EBITDA (p.s.) | -23.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.05 |
| PEG Ratio | 0 |
| Price to Book value | 0.14 |
| Price to Sales | 0.33 |
| Price to Cash Flow | -5.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|